Table 2.
Asthma features at baseline. Data represent the mean ± standard deviation, the median (25th, 75th percentile) or the number of participants (%).
| Lean N=257 |
Overweight N=99 |
Obese N=138 |
|
|---|---|---|---|
| Asthma control | |||
| Daytime symptoms >twice weekly | 95 (36.9) | 35 (35.4) | 70 (50.7)*^ |
| Nocturnal symptoms ≥twice monthly | 102 (39.7) | 43 (43.4) | 72 (52.2)* |
| ACQ-6 score | 0.98 ± 0.91 | 1.21 ± 1.09 | 1.23 ± 1.03* |
| Asthma quality of life | |||
| PAQLQ total score | 5.62 ± 1.25 | 5.27 ± 1.34* | 5.17 ± 1.23* |
| PAQLQ symptom domain | 5.54 ± 1.34 | 5.25 ± 1.38 | 5.10 ± 1.34* |
| PAQLQ activity domain | 5.61 ± 1.30 | 5.26 ± 1.43* | 5.31 ± 1.12* |
| PAQLQ emotional domain | 5.77 ± 1.39 | 5.45 ± 1.60 | 5.31 ± 1.56* |
| Asthma exacerbation (previous year) | |||
| Any exacerbation | 146 (58.6) | 71 (73.2) | 98 (71.0)* |
| ≥3 exacerbations | 59 (23.0) | 29 (29.3) | 52 (37.7)* |
| Emergency department visit | 109 (42.4) | 60 (60.6) | 83 (60.1)* |
| Hospitalization | 62 (24.2) | 30 (30.3) | 43 (31.2) |
| Lung function (% predicted value) | |||
| FVC | 100 ± 12.7 | 103 ± 12.3* | 104 ± 14.1* |
| FEV1 | 90.5 ± 14.9 | 90.0 ± 16.1 | 91.0 ± 16.5 |
| FEV1/FVC | 90.2 ± 11.1 | 86.3 ± 11.3* | 86.9 ± 9.3* |
| FEF25-75 | 71.5 ± 26.7 | 67.0 ± 26.3 | 68.6 ± 24.6 |
| FEV1 bronchodilator reversibility | |||
| Relative reversibility (%)1 | 12.8 ± 15.5 | 15.9 ± 16.9 | 13.8 ± 18.3 |
| Absolute reversibility (%)2 | 10.2 ± 10.8 | 12.7 ± 11.0 | 11.6 ± 11.8 |
| Exhaled nitric oxide (ppb) | 37.1 ± 37.4 | 33.2 ± 32.7 | 32.4 ± 28.1 |
| Methacholine PC20 (mg/mL)3 | 1.54 (0.43, 5.66) | 1.95 (0.72, 9.22) | 1.95 (0.82, 5.93) |
1
Defined as: (FEV1 post-bronchodilator – FEV1 pre-bronchodilator)/FEV1 pre-bronchodilator
2
Defined as: FEV1 post-bronchodilator %predicted – FEV1 pre-bronchodilator %predicted
3
lean, n=119; overweight, n=35; obese, n=39
*
p<0.05 vs. lean asthma
^
p<0.05 vs. overweight asthma